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ABSTRACT: 
Infection with Helicobacter pylori  (H. pylori) cagA-positive strain is associated with 
human malignancies such as gastric adenocarcinoma and mucosa-associated lymphoid 
tissue lymphoma (MALT) of B-lymphocyte origin. The cagA gene product, CagA is 
injected by the bacterium into gastric epithelial cells, where it subsequently undergoes 
tyrosine phosphorylation. Upon tyrosine phosphorylation, CagA acquires the ability to 
specifically binds to Src homology2 (SH2) domain-containing protein tyrosine 
phosphatase 2 (SHP2), activates the phosphatase activity and thereby promotes 
neoplastic transformation of cells. Here I show that CagA is also capable of interacting 
with the SHP2 homologue, SHP1 in gastric epithelial cells. However unlike SHP2, 
CagA-SHP1 interaction is completely independent of CagA tyrosine phosphorylation. I 
also demonstrated that CagA directly binds to SHP1 and the interaction requires the N-
terminal SH2 domain-containing region of SHP1 but not the functional SH2 domains. 
And such CagA-SHP1 interaction results in the activation of the phosphatase. I also 
found that SHP1 is a major and specific phosphatase that catalyzes the 
dephosphorylation of tyrosine-phosphorylated CagA. In striking contrast, expression of 
SHP2 did not result in the dephosphorylation of CagA both in gastric epithelial cells 
and in vitro. Furthermore, SHP1 but not SHP2 inhibits induction of the unique cell 
morphology termed ‘Hummingbird phenotype’, which is caused by tyrosine-
phosphorylated CagA. Taken together these results indicate that SHP1 tyrosine 
phosphatase is a specific inhibitor for the phosphorylation-dependent oncogenic action 
of H. pylori CagA that directs gastric carcinogenesis. 
 
 
	   5	  
Introduction: 
Infection with Helicobacter pylori (H. pylori) is associated with upper gastrointestinal 
diseases, including chronic gastritis, peptic ulcer diseases, gastric adenocarcinoma and 
mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach. Among various 
pathogenic bacterial effectors, which are delivered into host mammalian cells, special 
attention has been paid to those that undergo tyrosine phosphorylation by host cell 
kinases (6). Helicobacter pylori CagA is a prototype of such bacterial effectors. The 
cagA gene, which located in the cag pathogenicity island (PAI) in the H. pylori genome, 
encodes a 120-to 145-kDa immunodominant protein CagA (13, 72). Compared with 
cag-negative H. pylori strains, cag-positive strains significantly increase the risk of 
developing severe diseases including gastric carcinoma (33,58). The CagA protein is 
injected directly from the bacterium into gastric epithelial cells via type IV secretion 
system and localized to the inner side of the plasma membrane, where it undergoes 
tyrosine phosphorylation by Src family kinases (SFKs) such as c-Src, Lyn, Fyn, and 
Yes or c-Abl kinase at the Glu-Pro-Ile-Tyr-Ala (EPIYA) sequence-motif that is present 
in variable numbers in its C-terminal region (24,69,73). Depending on sequences 
surrounding each of the EPIYA-motif, four distinct EPIYA segments EPIYA-A, -B, -C, 
and –D have been described (23). Whereas the EPIYA-A and EPIYA-B segments are 
virtually present in all the CagA proteins, the EPIYA-C segment is specific to CagA of 
H. pylori isolated in Western countries (Europe and North America), Africa, Australia, 
and several Asian countries (Middle East, India and Malaysia), while the EPIYA-D 
segment is unique to CagA of H. pylori isolated in the far East (China, Japan and 
Korea). These EPIYA segments can appear in different numbers and configurations in 
different CagA species, making C-terminal CagA variations (7). Tyrosine-
	   6	  
phosphorylated CagA specifically binds to the Src-homology 2 (SH2) domain-
containing protein tyrosine phosphatase 2 (SHP2; also termed as PTPN11, Syp, SH-
PTP3, PTP-1) (2,19,76), a bona fide oncoprotein, gain-of-function mutations of which 
are associated with various human malignancies (106). CagA-deregulated SHP2 
perturbs the Erk-MAP kinase (27) and also dephosphorylates focal adhesion kinase 
(FAK) to induce an elongated cell-shape known as the hummingbird phenotype (89,90). 
CagA transgenic mice studies showed induction of abnormal proliferation of gastric 
epithelial cells as well as hematopoietic cells, followed by the development of 
gastrointestinal carcinomas and leukemias /lymphomas in a tyrosine phosphorylation-
dependent manner  (92). 
Tyrosine phosphorylation plays an important role in the signal transduction from the 
cell surface to the nucleus. Major member of proteins that down-regulate tyrosine-based 
signaling pathways by coordinately antagonizing the actions of protein-tyrosine kinases 
are protein tyrosine phosphatases (PTPs) (40). Because of their opposite catalytic 
functions, PTPs control a wide range of phosphotyrosine-mediated signaling pathways 
in metazoan. In mammalian genome, there are approximately 100 genes that potentially 
encode PTPs (reviewed in 87). Among these, two structurally related intracellular PTPs, 
SHP1 (also termed as PTPN6, SH-PTP1, PTP1C, HCP, or Hcph) (65,55,78,44) and 
SHP2 are unique in that they contain SH2 domains (3,22,52). They are capable of 
interacting with tyrosine-phosphorylated proteins via SH2 domains and indeed they 
have been shown to bind to multiple receptor molecules including cytokine receptors 
(18,34,80), receptor-type protein tyrosine kinases (19,65,75,76,79), antigen receptors 
(16,41,59), and adhesion molecules (31). In the absence of adequate stimuli, SHPs are 
considered to exist in their inactive configurations (104). SHP1 and SHP2 are 
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approximately 50% identical at their amino-acid levels (12,87,104). Although they 
belong to the same family and have similar catalytic and regulatory mechanisms, SHP1 
and SHP2 have different biological functions in vivo (104). SHP1 is expressed 
predominantly in hematopoietic cells of all lineages and all stages of maturation, 
however it is also expressed in epithelial cells (44, 49, 55, 65, 78). On the other hand 
SHP2 is a ubiquitously expressed PTP and positively regulates signal transduction 
events from a variety of activated receptor tyrosine kinases (2,19,21). Both SHP1 and 
SHP2 are non-transmembrane protein tyrosine phosphatases with a central catalytic 
domain, two SH2 domains at the N-terminus and a C-terminus with potential tyrosine 
phosphorylation sites (8, 32, 39, 51, 57, 71, 83) and involved in the regulation of 
cellular proliferation and survival (50). SHP1 is considered to act as a negative regulator 
of signal transduction in hematopoietic cells, terminating signals from a diverse range of 
signaling molecules including interleukin-3 receptor, c-Kit, receptor-associated JAK 
kinases, colony-stimulating factor-1 receptor and B and T cell antigen receptors 
(reviewed in 84). The essential role of SHP1 as a negative regulator of signal 
transduction is consistent with the multiple defects in hematopoietic cells observed in 
moth eaten mice, which lack functional SHP1 (93). Motheaten mice die soon after birth 
due to over-proliferation and accumulation of macrophages in the lungs (105). However 
functional role of SHP1 expressed in non-hematological cells including epithelial cells 
remains largely unknown (reviewed in 17).  
In this study I explored the role of SHP1 in H. pylori CagA-mediated gastric 
carcinogenesis. I found a novel interaction between SHP1, the SHP2 homologue and 
Helicobacter pylori CagA in gastric epithelial cells. Unlike CagA-SHP2 interaction 
however, the association between CagA-SHP1 is totally independent of the EPIYA-
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tyrosine phosphorylation of CagA. Consistent with this the interaction is independent of 
functional SH2 domains of SHP1, although it requires the SH2 domain-containing N- 
terminal region of SHP1. Using an in vitro binding assay, I also found that CagA 
directly interacts with SHP1 and activates its phosphatase activity in in vitro 
phosphatase assay system. Additionally, I show that SHP1 directly tyrosine-
dephosphorylates CagA both in vitro and in gastric epithelial cells. In striking contrast, 
SHP2 is not capable of dephosphorylating CagA under the same experimental 
conditions, highlighting that CagA is a specific substrate of SHP1. Finally, I show that 
ectopic expression of SHP1 not SHP2 in gastric epithelial cells inhibit induction of the 
‘Hummingbird phenotype’, an extremely elongated cell morphological change caused 
by CagA-SHP2 interaction, which is concomitantly associated with the reduced tyrosine 
phosphorylation levels of CagA in cells. These findings indicate a critical role of SHP1 
in counteracting pathogenic/oncogenic action of H. pylori CagA through 
dephosphorylation. The work also reveals opposing roles of SHP1 and SHP2 in CagA-
mediated neoplastic transformation of cells. 
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Purpose  
SHP1 tyrosine phosphatase is proposed as a tumor suppressor gene candidate in various 
hematopoietic cancers. The purpose of this study was to explore the role of SHP2-
related SHP1 tyrosine phosphatase in H. pylori CagA-mediated gastric carcinogenesis.  
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Material and Methods: 
Expression vectors: Human SHP1 cDNA (gift from Dr. T. Matozaki, Kobe University 
of Medicine, Japan) was Flag-tagged and cloned into pcDNA3-based mammalian 
expression vectors. All Flag-tagged SHP1 point mutants used in this work were 
generated from the human SHP1 cDNA by site-directed mutagenesis (Fig 7A). To 
disable SH2 domains of SHP1, arginine-30 of N-SH2 and arginine-136 of C-SH2 
domains were substituted with lysine (SHP1 R30K, SHP1 R136K, SHP1 R30, 136K) 
(30,71,83). To disable the PTP domain of SHP1, aspartic acid-419, cysteine-453 and 
arginine-459 were substituted with alanine, serine and methionine respectively (SHP1 
D419A, SHP1 C453S, SHP1 R459M) (45, 67,74). Hemagglutinin (HA)-tagged, wild 
type CagA (CagA- ABCCC derived from H. pylori NCTC11637 western strain) were 
cloned into pSP65SRα mammalian expression vectors (HA-CagA-ABCCC or HA-
CagA) (26,70). Generation of HA-tagged phosphorylation-resistant CagA (HA-PR 
CagA) in which all the tyrosine in the EPIYA motifs were substituted with 
phenylalanine (here denoted as HA-PR CagA) and CagA mutant lacking the EPIYA 
motif-containing region: deletion of amino acid residues from 868-1087 (HA-CagA 
ΔABCCC) has been described previously (26,70). HA-tagged PR CagA and CagA 
ΔABCCC were cloned into pSP65Srα mammalian expression vectors (26,70). Human 
SHP2 cDNA (derived from AGS cells) was Flag-tagged and cloned into pcDNA3-based 
mammalian expression vectors. For knockdown experiment, duplex small interference 
RNA (SiRNA) for human SHP1 (111) was synthesized by operon (Japan) and SiRNA 
for luciferase was synthesized by Greiner bio-one (Japan). Nucleotide sequence used 
were SHP1, sense 5’-AGCCUGGAGACUUCGUGCUUU-3’ and antisense 5’-
AGCACGAAGUCUCCAGGCUUU-3’ and luciferase-specific SiRNA was used as 
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silencer negative control, sense 5’-CGUACGCGGAAUACUUCGATT-3’ and antisense 
5’-UCGAAGUAUUCCGCGUACGTT-3’. 
Antibodies and Reagents: Anti-SHP1 polyclonal antibody C-19 (Santa Cruz 
Biotechnology), anti-Flag monoclonal antibody (M2) (Sigma-Aldrich), anti-HA 
polyclonal antibody (3F10) (Roche) were used as primary antibodies for 
immunoblotting and immunoprecipitation. Anti-HA polyclonal antibody (3F10) 
(Roche), Anti-HA monoclonal antibody (C29F4) (Cell Signaling), Anti-
phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology), anti-CagA 
polyclonal antibody (Austral Biological), anti-His polyclonal antibody (6C4) anti-GST 
polyclonal antibody (Santa Cruz Biotechnology) and anti-Actin polyclonal antibody C-
11 (Santa Cruz Biotechnology) were used as primary antibodies for immunoblotting. 
Cell culture and transfection: AGS human gastric epithelial cells were cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), at 37°C, under 
5% CO2 humidified atmosphere. 20 µg expression vectors were transiently transfected 
into 1.2×106 AGS cells in a 100-mm dish by using Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacture’s instructions. For immunoprecipitation, cell 
lysates were prepared 24 h after the transfection. For SHP1 knockdown experiment, 100 
pmol of SiRNA were transiently transfected into 4x105 AGS cells in a 60-mm dish by 
using lipofectamine 2000. After 24 h the cells were reseed, 12 h after reseeding, HA-
CagA expression vectors were transfected into AGS cells by using lipofectamine 2000 
(Invitrogen). BJAB cells (EBV-negative human burkitt’s lymphoma cells, Kindly 
provided by Dr. Ping-Ning Hsu, National Taiwan University, Taiwan) were cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, under 
5% CO2 humidified atmosphere. BJAB cells were infected with H. pylori for 24 h at a 
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multiplicity of infection (MOI) of 100 before harvest. For immunoprecipitation, cell 
lysates were prepared 24 h after the infection.   
Confocal microscopy: AGS cells were cultured in RPMI 1640 medium supplemented 
with 10% FBS. For transfection, 240 ng of plasmids was transfected into AGS cells 
(2×104 cells/0.8 cm2) by using 0.4 µl of Lipofectamine 2000 reagent (Invitrogen). After 
24 h incubation, cells were fixed with Mildform 10N (Wako) for 20 min and 
permeabilized with 0.5% Triton X-100 for 20 min. The cells were then treated overnight 
with primary antibody and were visualized with Alexa Flour 488-conjugated and 546-
conjugated anti-rabbit and anti-mouse antibody (Invitrogen) respectively. The nuclei 
were stained with 4’, 6-diamidino-2-phenylindole (DAPI). Images were acquired using 
confocal microscope system (FV 1200, Olympus). 
Immunoprecipitation and immunoblotting: AGS cells or BJAB cells were lysed in 
lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.5 % NP-40, 
0.25 % Sodium-deoxycholate, 1 mM Na3VO4, 2 mM phenylmethylsulfonylfluoride 
(PMSF), 10 µg/ml leupeptin, 10 µg/ml trypsin inhibitor, 10 µg/ml aprotinin). Cell 
lysates were treated with specific antibodies, and immune complexes were trapped on 
protein G-Sepharose beads. Total cell lysates and immunoprecipitates were subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins 
transferred to polyvinylidene difluoridemembrane filter (Millipore) were soaked in 
solutions of primary antibodies (1:1000, 90 min at room temperature) and then with 
secondary antibody (1:10,000, 45 min at room temperature). Proteins were visualized 
by using western blot chemiluminescence reagent (Perkin-Elmer Life Sciences). 
Intensity of protein band was quantitated by a luminescence image analyzer (LAS-4000, 
FUJIFILM). 
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Bacteria: H. pylori NCTC11637 strain and its cagA-defective isogenic strains (ΔcagA) 
have been reported previously (26). BJAB cells (Burkitt’s Lymphoma Cells) were 
infected with H. pylori NCTC11637 or the isogenic ΔcagA strain for 24 h at a 
multiplicity of infection (MOI) of 100 before harvest. 
Construction and expression of recombinant proteins: Bacterial expression vectors 
for the glutathione S-transferase (GST), fused SHP1 proteins used in this study were 
made by sub cloning the following cDNA- or PCR-amplified fragments into pGEX6P-1 
using EcoR1 (5’-end) and Not1 (3’-end) enzyme site: the full-length human SHP1 
cDNA (1-595), a full length human SHP1 cDNA containing a Cys453-Ser mutation 
(SHP1 C453S), the human SHP1 cDNA fragment encoding the COOH-terminal region 
(247-595) (SHP1 ΔN). Bacterial expression vectors for GST fused SHP2 proteins were 
made by sub cloning the full-length human SHP2 cDNA into pGEX6P-2 using Bam1 
(5’-end) and Sal1 (3’-end) enzyme site. GST fused SHP1 or SHP2 expression plasmids 
were transformed into Escherichia coli BL21 (DE3) and GST fusion proteins were 
purified as described previously (29). Briefly a single colony was inoculated into 100 
ml of LB medium containing 100 µg/µl ampicillin and cultured overnight. Eighty ml of 
this overnight culture were added to 1.5 L of LB media containing, ampicillin and 
grown at 37°C to OD600 = 0.8. Isopropyl-1-thio-β-D-galactopyranoside (IPTG) was 
added to a final concentration of 100 mM, and the bacteria were kept 16 h at 25°C under 
shaking. Then the bacteria were pelleted at 6,000 × g and 4°C, for 10 min. The pellet 
was resuspended in 150 ml of equilibration buffer containing 25 mM Tris-HCl, (pH 
7.5), 150 mM NaCl, 5 mM EDTA, 10 mM β -mercaptoethanol, with 0.3 mg/ml 
benzamidine. To the suspension lysozyme was added (0.5 mg/ml final concentration), 
and the mixture was incubated at 25°C for 20 min. Subsequently EDTA and Triton X-
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100 were then added at a final concentration of 20 mM and 0.5 %, respectively, and the 
mixture was incubated for another 20 min. The bacterial lysate was centrifuged at 
30,000 × g and 4°C for 40 min and the supernatant was transferred to a fresh 50-ml 
polypropylene tube containing 3 ml bed of Glutathione-Sepharose 4B (GE Healthcare). 
This suspension was mixed by end-over-end rotation for 1 h at 4°C and then charged 
this bead slurry into empty column (Bio-Rad) and beads were washed 3 times at 4°C 
with 30 ml of W1 buffer (25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 % Triton X-100, 
10 mM β-mercaptoethanol) and 3 times with 30 ml of W2 buffer (50 mM Tris-HCl (pH 
8.0), 150 mM NaCl, 10 mM β-mercaptoethanol). The bound proteins were incubated 
with 15 µl of preScission protease (GE Healthcare) in 3 ml of W2 buffer at 4°C for 16 h. 
Released protein fraction (3 ml) and additional washout fraction with 7 ml of W2 buffer 
were collected, and the protein concentration was determined using Bradford method. 
Details on the purification of recombinant CagA have been described previously (28). 
In brief, the full-length cagA gene was isolated by PCR from H. pylori 26695 and was 
inserted into pGEX-6P-2 (GE Healthcare) with a C-terminal hexahistidine-tag 
sequence. Recombinant CagA proteins expressed by E. coli BL21 (DE3) were cultured 
with Terrific-broth at 37°C. Protein expression was induced at OD600 of 0.7-1.0 by 0.4 
mM IPTG for 2 h at 30°C. Bacterial pellets were re-suspended in 20 mM Tris-HCl (pH 
8.0), 100 mM MgCl2, 10 mM imidazole, and 0.3 mg/ml benzamidine and lysed by 
ultrasonication. The soluble fraction of the sample was applied to nickel-nitrilotriacetic-
acid (Ni-NTA) agarose beads (QIAGEN), washed with 20 mM imidazole containing 
buffer, and eluted with 250 mM imidazole containing buffer. The elutes were applied to 
Glutathione Sepharose 4B beads (GE Healthcare) and washed with 50 mM Tris-HCl 
(pH 7.3), 150 mM NaCl, 5 mM EDTA, and 2 mM DTT followed by 50 mM Tris-HCl 
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(pH 7.0), 150 mM NaCl, 1 mM EDTA, and 1 mM DTT. The GST-tags were excised by 
the in-gel digestion method with PreScission protease (GE Healthcare) and the unbound 
fractions were collected. After buffer change in 20 mM Tris-HCl (pH 8.0), 500 mM 
NaCl on a Hiprep 26/10 Desalting column (GE Healthcare), the proteins were applied to 
a HisTrap HP Ni-affinity column (GE Healthcare), washed with a linear gradient of 0-
40 mM imidazole, and eluted with 250 mM Imidazole. Finally, gel-filtration 
chromatography was performed using Superose 6 (GE Healthcare) in 20 mM Tris-HCl 
(pH 8.0), 500 mM NaCl. The purified proteins were concentrated to 50-60 mg/ml using 
Amicon Ultra-4 (50,000 MWCO, Millipore). For the expression of tyrosine-
phosphorylated CagA (pY CagA-His) in E. coli, bacterial expression vectors for 
recombinant v-Src was introduced together with the recombinant CagA expression 
vector into E. coli strain BL21 (DE3). Briefly, the v-src gene was cloned into a bacterial 
expression vector pACYCDuet1 using Not1 enzyme site and the resulting 
pACYCDuet1-v-Src were co expressed with pGEX-6P-2 CagA in BL21 (DE3) for 
generating tyrosine-phosphorylated CagA. Resulting E. coli, BL21 (DE3) were cultured 
with Terrific-broth at 37°C and protein expression was induced at OD600 of 1.0 by 0.1 
mM IPTG, for shaking culture overnight at 18°C. For the purification of the 
recombinant tyrosine-phosphorylated CagA protein (pY CagA-His) from the bacterial 
pellets, I followed the same protocol as mentioned above for recombinant CagA protein 
(Lisa Nagase et al., manuscript under preparation). 
In vitro phosphatase assay. In vitro phosphatase assay were carried out as described 
previously (46,83). In brief, para-nitrophenylphosphate (pNPP) (Wako) was used as a 
substrate to determine the phosphatase activity of the recombinant SHP1. The 
phosphatase assay were carried out at 37°C for 30 min in 50 µl of reaction buffer (100 
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mM Na-HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, and 10 mM dithiothreitol, 10 
mM pNPP) with 1 µM SHP1 in the absence or presence of 10 µM CagA-His. The 
reactions were quenched with 950 µl of 1N NaOH. The phosphatase activity was 
determined and quantitated by measuring the spectrophotometric absorbance of the 
reaction product p-nitrophenolate at A405. For in vitro CagA phosphatase assay, 
phosphorylated CagA (pY CagA-His) was mixed with wild-type SHP1, wild-type 
SHP2, or phosphatase-dead SHP1 C453S. Phosphatase reactions were carried out at 
37°C for 60 min in 30 µl of phosphatase buffer (25 mM HEPES (pH 7.4), 2.5 mM 
EDTA, 5 mM dithiothreitol, 50 mM NaCl, 65 ng/µl BSA) and reaction was stopped by 
adding SDS sample buffer and boiling at 100°C. Samples were analyzed by SDS-PAGE 
and western blotting with an anti-phosphotyrosine (anti-pY) antibody. 
In vitro binding assay. For in vitro binding assay, GST, GST-pY CagA-His, or GST- 
CagA-His was incubated with wild-type SHP1 or phosphatase-dead SHP1 (SHP1 
C453S) or C-terminal region of SHP1 (amino-acid residues 247-595) (SHP1ΔN) at 4°C 
for 1 h and washed 5 times in pull down buffer (50 mM Tris-HCl (pH 7.5), 5 mM 
EDTA, 150 mM NaCl, 0.01%Triton X-100). Protein complexes were collected with 
GST-fused beads and were analyzed on SDS-PAGE, followed by Western blotting with 
an anti-phosphotyrosine (anti-pY), anti-SHP1, anti-His or anti-GST antibody. 
Cell-morphological analysis & Hummingbird assay. The morphology of the AGS 
cells was observed at 17 h after transfection as described previously (48,69). AGS cells 
were transiently transfected with expression vectors and after 17 h incubation cell 
morphology was examined by light microscopy. Cells showing the hummingbird 
phenotype were counted in 10 different fields in each of four dishes (the area of one 
field = 0.25 mm2). To investigate cell-morphology in more detail, the images of the 
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AGS cells were captured at 24 h after transfection by using confocal microscope system 
(FV 1200, Olympus). Hummingbird phenotype was defined as an elongated cell-shape, 
in which the ratio of the longest protrusion of cell to the shortest cell diameter is more 
than 2-fold.  
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Results: 
1. CagA associates with SHP1 tyrosine phosphatase in AGS cells and B cells. 
It was demonstrated previously that upon delivery into the host cell, H. pylori CagA 
forms a physical complex with SHP2 (24) in gastric epithelial cells. To examine 
whether CagA can also form a physical complex with the SHP2 homologue SHP1, I 
transiently co-transfected the HA-tagged wild-type CagA (HA-CagA) vector and the 
Flag-tagged SHP1 (Flag-SHP1) vector in AGS cells and through sequential 
immunoprecipitation-western blotting experiment, it was found that CagA forms a 
physical complex with SHP1 (Fig 1A). Recent reports demonstrated that H. pylori can 
deliver CagA directly into B cells, via the type IV secretion system (35,42) and the 
translocated CagA formed a complex with SHP2 (35,42). Since SHP1 is abundantly 
expressed in hematopoietic cells including B cells (reviewed in 84), I wondered if 
infection with cagA-positive H. pylori could also give rise to the generation of the 
CagA-SHP1 complex in B cells. I therefore performed H. pylori infection experiment 
(moi: 100) using human lymphoma derived B cell line (BJAB). BJAB cells were 
infected with H. pylori cagA-positive strain or isogenic cagA-negative strain as a control 
and it was found that bacterially delivered CagA efficiently interacted with endogenous 
SHP1 in B cells (Fig 1B). Taken together, these results indicated that H. pylori 
oncoprotein CagA interacts with SHP1 in B cells as well as in gastric epithelial cells. 
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Figure 1  
 
             
Figure 1. Interaction between CagA and SHP1 in AGS and B cells.  (A) AGS cells 
were co-transfected with Flag-SHP1 and HA-CagA vectors. Total cell lysates (TCLs) 
were immunoprecipitated with anti-HA antibody and the immunoprecipitates (IPs) were 
subjected to immunoblotting with the indicated antibodies. (B) BJAB cells were 
infected with the H. pylori cagA-positive or the cagA-negative isogenic strain (Δ cagA) 
for 24 h. Total cell lysates (TCLs) were immunoprecipitated with an anti-CagA 
antibody and the immunoprecipitates (IPs) were subjected to immunoblotting with the 
indicated antibodies. Each experiment was repeated at least three times and the 
representative data were shown. 
 
2. CagA-SHP1 interaction is independent of tyrosine phosphorylation of CagA at 
EPIYA motif. 
The cagA gene product CagA undergoes tyrosine phosphorylation at the C-terminal 
EPIYA motifs when expressed in mammalian cells (24,69). Since SHP2 binds to CagA 
in a manner that is dependent on CagA EPIYA tyrosine phosphorylation and next I 
investigated whether the observed CagA-SHP1 interaction was also dependent on CagA 
tyrosine phosphorylation. To this end, I transiently transfected a Flag-SHP1 vector 
together with an expression vector for HA-tagged wild type CagA (HA-CagA) or HA-
tagged phosphorylation resistant CagA (HA-PR CagA, in which all the tyrosine’s in the 
EPIYA motifs were substituted by phenylalanine residues) in AGS cells and found that 
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PR CagA was also capable of binding with SHP1 (Fig 2A). To consolidate 
phosphorylation-independent interaction of CagA with SHP1, HA-PR CagA or HA-
CagA vector was transfected into AGS cells and the cell lysates were 
immunoprecipitated with an anti-SHP1 antibody. The resulting anti-SHP1 
immunoprecipitates contained WT and PR CagA (Fig 2B). These observations 
indicated that CagA forms a complex with endogenous SHP1 in a CagA 
phosphorylation-independent manner. In addition to CagA phosphorylation, the 
EPIYA-containing region of CagA exerts multifaceted functions such as PAR1 
interaction (91). Accordingly I next investigated whether the EPIYA-containing region 
is still responsible for SHP1 interaction independent of EPIYA tyrosine-
phosphorylation. To do so, I transiently transfected an expression vector for HA-CagA 
or a HA-CagA mutant in which the EPIYA-containing region was deleted (HA-CagA 
ΔABCCC) (25) together with the Flag-SHP1 vector. The result of the experiment 
revealed that HA-CagA ΔABCCC was still capable of binding SHP1 (Fig2C). I thus 
concluded that the EPIYA-containing region does not play a major role in the CagA-
SHP1 interaction. From these observations, I concluded that unlike CagA-SHP2 
interaction, H. pylori oncoprotein CagA interaction with SHP1 tyrosine phosphatase is 
totally independent of CagA tyrosine phosphorylation and EPIYA-containing region of 
CagA. 
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Figure 2 
 
         
                
 
Figure 2. CagA-SHP1 interaction is independent of tyrosine phosphorylation of 
CagA at EPIYA motifs. (A) AGS cells were transfected with Flag-SHP1 and HA-
CagA or HA-PR CagA (in which all the tyrosine in the EPIYA-motifs were substituted 
by phenylalanine). Total cell lysate (TCLs) were immunoprecipitated with anti-HA 
antibody, and the immunoprecipitates (IPs) were subjected to immunoblotting with the 
indicated antibodies. (B) AGS cells were transfected with HA-CagA or HA-PR CagA. 
Total cell lysates (TCLs) were immunoprecipitated with anti-SHP1 antibody and the 
immunoprecipitates (IPs) were subjected to immunoblotting with the indicated 
antibody. (C) AGS cells were transfected with Flag-SHP1 and HA-CagA or HA-CagA 
ΔABCCC (in which the EPIYA-containing region were deleted as shown in the 
schematics). Total cell lysates (TCLs) were immunoprecipitated with anti-HA antibody 
and the immunoprecipitates (IPs) were subjected to immunoblotting with the indicated 
antibody. Each experiment was repeated at least three times and the representative data 
were shown. 
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3. H. pylori CagA interact directly with SHP1 tyrosine phosphatase. 
To determine whether the CagA-SHP1 interaction I observed in the cells were direct or 
not, I carried out an in vitro binding assays using recombinant SHP1 and GST, GST-
fused phosphorylated CagA (GST-pY CagA-His) or GST-fused unphosphorylated 
CagA (GST-CagA-His) (described in Materials and Methods) immobilized on 
glutathione beads. Consistent with my cells data, both phosphorylated (GST-pY CagA-
His) and unphosphorylated (GST-CagA-His) CagA bound to SHP1 upon in vitro 
mixing of the two proteins (Fig 3A). These results indicate that SHP1 directly interacts 
with CagA and the interaction is entirely independent of the tyrosine phosphorylation of 
CagA. 
Figure 3 
 
Figure 3. H. pylori CagA interact directly with SHP1 tyrosine phosphatase. (A) In 
vitro pull down assay were performed using recombinant SHP1 and GST, GST-pY 
CagA-His (phosphorylated CagA) or GST-CagA-His and pull down samples were 
subjected to immunoblotting with the indicated antibodies. Experiment was repeated at 
least three times and the representative data was shown. 
 
4. SHP1 interacts with CagA through its N-terminus, independent of SH2 domain-  
phosphotyrosine interaction. 
Since SHP1 is occasionally recruited to its substrates by utilizing one or both of its SH2 
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domains (60), I next asked if the SH2 domains are responsible for mediating direct 
interaction of SHP1 with CagA. To this end, I generated a truncated form of 
recombinant SHP1 consisting exclusively of the carboxyl region [aa 247 to 595 
(SHP1ΔN)]. The result of the in vitro binding assay using full-length SHP1 or SHP1ΔN 
revealed that full-length SHP1 but not SHP1ΔN bound to GST-CagA-His, indicating 
that N-terminal region of SHP1, which contains the two SH2 domains is required for 
CagA binding (Fig 4B). Given this, I next performed an in vitro binding assay using 
GST or GST-pY CagA-His and SHP1 or catalytically inactive-mutant of SHP1 (SHP1 
C453S), which has been described as a substrate-trapping mutant (45). It was found that 
SHP1 C453S exhibited strongly elevated binding with GST-pY CagA-His (Fig 4C). 
These data together suggest that SHP1 binds to CagA via N-terminus and mutation in 
the PTPase domain may further facilitate or stabilize SHP1-CagA interaction. 
Figure 4 
                        A 
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Figure 4. N-terminus of SHP1 directly binds to CagA independent of SH2 domain-
phosphotyrosine interaction. (A) Different SHP1 constructs used in this experiments 
is shown in the schematics. (B) In vitro pull down assay was performed using 
recombinant full length SHP1 or truncated SHP1 with N-terminus deleted (denoted as 
SHP1ΔN) and GST or GST-CagA-His and samples were subjected to immunoblotting 
with the indicated antibodies. (C) In vitro pull down assay was performed using 
recombinant SHP1 or catalytically inactive-SHP1 C453S and GST, GST-pY CagA-His 
(phosphorylated CagA) and samples were subjected to immunoblotting with the 
indicated antibodies. Each experiment was repeated at least three times and the 
representative data were shown. 
 
5. Co-localization of CagA-SHP1 complex on the cell membrane.  
It is widely recognized that SHP1 is a cytoplasmic phosphatase (3,20,61,84). However, 
a novel nuclear localization signal for SHP1 has also been demonstrated in non-
hematopoietic cells (12). Therefore, intracellular localization of SHP1 may differs 
between hematopoietic and non-hematopoietic cells, in fact SHP1 protein is virtually 
exclusively cytoplasmic in hematopoietic cell lines and in the nucleus in some epithelial 
cells (12). Given this, I wished to know the subcellular localization of SHP1 in AGS 
human gastric epithelial cells that I used in this study. I overexpressed Flag-SHP1 in 
AGS cells and performed immunostaining experiment and staining images were 
acquired using confocal microscope system (FV 1200, Olympus). It was found that 
SHP1 broadly distributed in the nucleus and in the cytoplasm in AGS cells (Fig 5A). 
Next, to examine the co-localization of CagA-SHP1 complex in the cells, I co-express 
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HA-CagA and Flag-SHP1 in AGS cells. It was demonstrated previously that once 
delivered into the host cells H. pylori CagA localized to the cell membrane and 
undergoes tyrosine phosphorylation by Src family kinases (24,69). Here I show that in 
the presence of CagA, SHP1 was co-localized with CagA on the membrane periphery 
(Fig 5B). The results indicate cytoplasmic/nuclear localization of SHP1 in gastric 
epithelial cells, and at the same time provide further evidence that CagA-SHP1 forms a 
complex in the membrane periphery. 
Figure 5 
 
Figure 5. Localization of CagA-SHP1 complex. (A) AGS cells were transfected with 
a Flag-SHP1vector and were stained with an anti-Flag (SHP1: red) antibody. (B) AGS 
cells co-transfected with Flag-SHP1 and HA-CagA vectors were double stained with 
anti-Flag (SHP1: red) and anti-HA (CagA: green) antibodies. Nuclei (blue) were 
visualized by DAPI staining. Each experiment was repeated at least three times and the 
representative images were shown. 
 
6. CagA activates SHP1 phosphatase activity. 
The N-terminal region of SHP1 is involved in CagA binding. Previous studies have 
already shown that the phosphatase activity of SHP1 is up-regulated by peptide-binding 
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to the SH2 domains at the N-terminal region (57,108,109,110). Interaction of CagA 
with the N-terminal region of SHP1 suggested that the complex formation affects SHP1 
phosphatase activity. I therefore examined the phosphatase activity of the recombinant 
SHP1 (1 µM) protein in the absence or presence of recombinant CagA protein (10 µM). 
As shown in Figure 6, SHP1 phosphatase activity was significantly increased in the 
presence of CagA. These data indicates that CagA activates phosphatase activity of 
SHP1 through its binding to the N-terminal region of SHP1. 
Figure 6 
 
Figure 6. CagA activates SHP1 phosphatase activity. The phosphatase activity of 
recombinant SHP1 protein was measured using pNPP as a substrate in the absence or 
presence of recombinant CagA as indicated. Error bars, mean ± S.D. (n=3), *p < 0.01 
(student’s t test).  
7. SHP1 expression reduces the tyrosine phosphorylation level of H. pylori CagA in 
gastric epithelial cells. 
Since SHP1 is a protein tyrosine phosphatase, an intriguing idea is that CagA is 
tyrosine-dephosphorylated by SHP1. I therefore investigated the effect of SHP1 on the 
tyrosine phosphorylation status of CagA in epithelial cells by ectopically expressing 
wild-type SHP1 or its mutants (shown in Fig 7A). Overexpression of HA-CagA with 
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Flag-SHP1 in AGS cells caused a substantial reduction in the level of CagA tyrosine 
phosphorylation (Fig 7B). Next to see whether the reduced CagA phosphorylation was 
dependent on the catalytic activity of SHP1, HA-CagA was co-expressed with Flag-
SHP1 or a catalytically inactive-SHP1 mutants in which aspartic acid 419, cysteine 453 
and arginine 459 in the catalytic center was replaced by alanine, serine and methionine 
respectively (D419A, C453S and R459M) (45, 67,74). Upon expression in AGS cells, 
wild-type SHP1 reduced the level of CagA tyrosine phosphorylation, whereas the 
catalytically inactive-mutants (D419A, C453S, R459M) all failed to do so (Fig 7B, C). 
These data provided compelling evidence that SHP1 phosphatase activity is essentially 
required for the reduced levels of CagA tyrosine phosphorylation in cells. SH2 domains 
of SHP1 are important in recruiting phosphotyrosine-containing proteins, controlling 
substrate specificity as well as cellular localization of SHP1. Mutations in the SH2 
domains have been shown to influence the functions and activities of SHP1 (30,57, 
71,83). To investigate the potential involvement of the SH2 domains of SHP1 in the 
tyrosine dephosphorylation of CagA, I next investigated a series of SH2 domain-
mutants of SHP1. R30K mutation abolishes the function of N-SH2 domain of SHP1 
whereas R136K substitution abolishes the function of C-SH2 domain of SHP1 (Fig 7A)  
(30,71,83). I generated an expression vector for a Flag-tagged SHP1 mutant carrying 
R30K, R136K or both and transfected it into AGS cells together with HA-CagA and 
found that these SH2 domain-mutants were still capable of inducing CagA 
dephosphorylation in AGS cells (Fig 7D). The results argue against the idea that the 
functional SH2 domains of SHP1 is involved in the tyrosine dephosphorylation of CagA 
upon ectopic expression of SHP1. 
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Figure 7  
                        A        
 
 
 
Figure 7. SHP1 dephosphorylates CagA in AGS cells. (A) Schematics of human 
SHP1 and its various point mutants used in this experiments. (B) AGS cells were 
transfected with HA-CagA alone or together with Flag-SHP1 or catalytically inactive-
Flag-SHP1 C453S vectors. Total cell lysates (TCLs) were immunoprecipitated with 
anti-HA antibody and the immunoprecipitates (IPs) were subjected to immunoblotting 
with the indicated antibodies. (C) AGS cells were transfected with HA-CagA vector 
alone or together with Flag-SHP1, or Flag-SHP1 R459M, Flag-SHP1 D419A and Flag-
SHP1 C453S vectors. Cell lysates were subjected to immunoblotting with the indicated 
antibodies. (D) AGS cells were transfected with HA-CagA vector alone or together with 
Flag-SHP1, or Flag-SHP1 R30K, Flag-SHP1 R136K, Flag-SHP1 R30, 136K, Flag-
SHP1 C453S vectors. Cells lysates were subjected to immunoblotting with the indicated 
antibodies. Each experiment was repeated at least three times and the representative 
data were shown. 
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8. Dephosphorylation of H. pylori CagA oncoprotein by SHP1 in vitro. 
These above mentioned observations indicated that SHP1 is a phosphatase that tyrosine-
dephosphorylates H. pylori oncoprotein CagA. To investigate this possibility, I carried 
out an in vitro phosphatase assays using recombinant SHP1 and tyrosine-
phosphorylated CagA (pY CagA-His) at 37°C for 60 min in 30 µl of phosphatase buffer. 
The CagA-His protein was phosphorylated using the v-Src kinase co-expressed in E. 
coli and after purification was used as a substrate of in vitro phosphatase assays. 
Consistent with the cells data, in vitro incubation of pY CagA-His protein with SHP1 
efficiently dephosphorylated pY CagA (Fig 8A), indicating that CagA is a 
dephosphorylation substrate of SHP1 in vitro. In vitro phosphatase assay was also 
performed using phosphorylated CagA (pY CagA-His) and a phosphatase-dead mutant 
of SHP1 in which cysteine 453 in the catalytic center was replaced with serine (SHP1 
C453S, hereby referred to as CS). The CS mutant lacks the PTP activity while retaining 
the ability to bind substrates (45). In contrast to wild-type SHP1, the SHP1 CS mutant 
failed to dephosphorylate CagA (Fig 8B) indicating that the intact catalytic activity is 
required for dephosphorylation of CagA by SHP1. However, the possibility still existed 
that any phosphatases could non-specifically dephosphorylate CagA in the in vitro 
phosphatase assay. Accordingly I also investigated the ability of the SHP1-related SHP2 
in dephosphorylating CagA in the in vitro phosphatase assay. Notably, there was no 
change in the phosphorylation status of pY CagA-His in the presence of wild-type 
SHP2 (Fig 8C). On the other hand, SHP1 efficiently dephosphorylated pY CagA-His at 
1 µM (lane 3) and almost totally dephosphorylated pY CagA-His at 5 µM (lane 5). The 
results of the experiment clearly indicated that SHP2 did not dephosphorylate CagA and 
argue for a strict substrate specificity of SHP1 towards CagA. 
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Figure 8 
 
 
 
Figure 8. SHP1 specifically dephosphorylates CagA in vitro. (A) Tyrosine 
phosphorylated CagA-His (pY CagA-His) (1 µM) was used as the substrates in 
phosphatase assay with recombinant wild type SHP1 (1 µM) and samples were 
subsequently analyzed for residual tyrosine phosphorylation (pY) by immunoblotting 
with the indicated antibodies. (B) Equal aliquots (1 µM) of tyrosine-phosphorylated 
CagA-His (pY CagA-His) were used as the substrates in phosphatase assay with the 
bacterially expressed, purified WT (1 µM) or C453S mutant of SHP1 (1 µM) and 
samples were analyzed for residual tyrosine phosphorylation by immunoblotting with 
the indicated antibodies. (C) Equal aliquots of tyrosine phosphorylated CagA-His (pY 
CagA-His) (5 µM) were used as a substrates in phosphatase assays with the indicated 
amounts of recombinant SHP2 (1 µM, 5 µM) and SHP1 (1 µM, 5 µM). Samples were 
subsequently analyzed for residual tyrosine phosphorylation by immunoblotting with 
indicated antibodies. Each experiment was repeated at least three times and the 
representative data were shown. 
 
9. Elevated tyrosine phosphorylation of CagA in SHP1-knockdown epithelial cells. 
From the result of the above-described experiments, over expression of SHP1 was 
found to cause tyrosine dephosphorylation of CagA. Next to see whether the observed 
phenomenon is physiologically relevant, I performed SHP1-knockdown experiment in 
	   31	  
AGS cells using SHP1-specific SiRNA. As shown in figure 9, knockdown of SHP1 in 
AGS cells resulted in the increase of tyrosine phosphorylation of CagA indicating that 
SHP1 is indeed acting as the phosphatase that dephosphorylates H. pylori oncoprotein 
CagA.    
Figure 9 
 
Figure 9. Effects of SHP1 knockdown on the level of CagA tyrosine 
phosphorylation in AGS cells. AGS cells were transfected with the indicated specific 
SiRNA. Cell lysates were then prepared and subjected to immunoblotting with the 
indicated antibodies. Experiment was repeated at least three times and the representative 
data was shown. 
 
10. Expression of SHP1 inhibits a unique cell-morphological change caused by 
tyrosine-phosphorylated H. pylori CagA. 
Expression of CagA in AGS cells, either by infection with cagA-positive H. pylori or 
transfection of a CagA expression vector induces an elongated cell morphology termed 
the ‘hummingbird phenotype’. The morphological change, which is characterized by 
development of one or two long protrusions, requires aberrant activation of SHP2 by 
CagA that has been tyrosine-phosphorylated at the EPIYA-C or EPIYA-D segment. 
This cell-morphological change is associated with cell scattering and increased cell 
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motility (24,48,63). From the results of the above-described experiments, SHP1 was 
found to act as a specific phosphatase of CagA. This in turn indicated that SHP1 
counteracts the ability of CagA to induce the hummingbird phenotype as this 
phenomenon is entirely depend on the tyrosine phosphorylation of CagA. To investigate 
this, I transfected a HA-CagA vector alone or together with a Flag-SHP1 vector in AGS 
cells. After 17 h, cell morphology was examined by light microscopy (Fig 10A). It was 
found that the numbers of hummingbird cells were significantly reduced in cells 
expressing SHP1 (Fig 10A). At this time point cells were harvested and immunoblotted. 
Again as shown in (Fig 10A) the level of CagA tyrosine phosphorylation was reduced 
upon SHP1 expression. To investigate cell-morphology in more detail, the images of the 
AGS cells were captured at 24 h after transfection by using confocal microscope 
system. AGS cells were transfected with EGFP or HA-CagA alone or together with 
Flag-SHP1 or with Flag-SHP2 vectors. The hummingbird phenotype induced by CagA 
was inhibited in cells expressing SHP1 but not SHP2 (Fig 10B). These results indicated 
that SHP1 dampens the pathogenic/oncogenic potential of H. pylori CagA upon tyrosine 
dephosphorylation. 
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Figure 10  
   
 
Figure 10. SHP1 inhibits cell-morphological change caused by tyrosine-  
phosphorylated CagA. (A) AGS cells were transfected with a HA-tagged CagA alone 
or together with Flag-tagged SHP1 vector and cell morphology was observed by light 
microscopy at 17 h after transfection. Red arrows indicate hummingbird cells induced 
by CagA. The number of hummingbird cells induced by CagA alone or in the presence 
of SHP1 were counted and percentage of hummingbird cells was quantified. Error bars, 
mean ±S.D. (n=3), *p < 0.01 (student’s t test). At this time points, total cell lysates 
(TCL) were also prepared and were subjected to immunoblotting (IB) with the indicated 
antibodies. (B) AGS cells were transfected with HA-CagA alone or together with Flag-
SHP1 or Flag-SHP2 vectors and cells were stained with anti-HA (CagA: green), and 
anti-Flag (SHP1 and SHP2: red) antibody. Nuclei were stained with DAPI (blue). 
Confocal images are shown. Yellow arrows indicate hummingbird cells induced by 
CagA. The number of hummingbird cells induced by HA-CagA alone or together with 
Flag-SHP1 and Flag-SHP2 were counted and percentage of hummingbird cells was 
quantified. Error bars, mean ±S.D. (n=3), *p < 0.01 (student’s t test). Total cell lysates 
(TCL) were also prepared and were subjected to immunoblotting (IB) with the indicated 
antibodies. 
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DISCUSSION 
CagA is a major virulence factor of Helicobacter pylori, a causal agent for various 
gastro duodenal diseases ranging from gastritis to gastric cancer. This bacterial protein 
is delivered into the host gastric epithelial cells via the bacterial Type IV secretion 
system (1,4,53,62,63). Upon delivery, CagA disturbs the intrinsic signal transduction by 
targeting the signal molecules of the host cells (4). The best-characterized cellular target 
of CagA is SHP2 tyrosine phosphatase, an oncoprotein, gain-of-function mutation of 
SHP2 has been found in a variety of human cancers (24,88). The CagA-SHP2 
interaction is totally dependent on the tyrosine phosphorylation of CagA at the EPIYA-
segment (24). CagA-deregulated SHP2 elicits augmented activation of the 
promitogenic/prooncogenic Erk-MAP kinase signaling pathway while inducing the 
morphological changes in gastric epithelial cells, which is characterized by the 
elongation of cell shape with thin protrusion, is known as hummingbird phenotype. This 
cell-morphological change is associated with cell scattering and increased cell motility 
(24, 27, 48,63). 
Two SH2 domain-containing phosphotyrosine phosphatases, SHP1 and SHP2 are 
widely implicated in the regulation of signaling pathways involved in cell proliferation, 
differentiation and survival (96). These PTPs are involved in the pathogenesis of 
lymphoma, leukemia and other types of cancers (97,98). Despite their high degree of 
homology, SHP1 and SHP2 have distinct expression profiles and functions. In contrast 
to SHP2, which is ubiquitously expressed, SHP1 is mainly found in hematopoietic cells 
(44). Multiple binding partners and substrates of SHP1 have been identified. For 
example, SHP1 acts as a negative regulator of several signal transduction proteins 
	   35	  
including cytokine receptors, by dephosphorylating the receptor itself and/or receptor-
associated kinases such as Src and JAK family kinases (30,82). This PTP can also down 
regulate the activation of STATs (99). SHP1 has been implicated in negative signaling 
through inhibitory receptors (ITIM). Inhibitory receptors play a vital role in regulating 
the cells of immune system (106). The role of the ITIM was first elucidated in B cells. 
The importance of the inhibitory signals delivered by SHP1 is highlighted by the 
motheaten (me) mouse, which has a natural mutation in the SHP1 locus (106). Mice 
with this deficiency are characterized by a widespread autoimmune phenomenon, 
caused by an inability to negatively regulate immune responses (59, 79, 80, 93, 94, 95). 
Furthermore, recent reports have clearly shown that the absence of SHP1 or decrease in 
the level of SHP1 protein expression is frequent in malignant T cells and it results from 
the methylation of SHP1 gene promoter (100,101,102). Because the enforced 
expression of SHP1 reverses the malignant phenotype, the phosphatase has been 
proposed as a tumor suppressor gene candidate in various hematopoietic cancers (103).  
In contrast to hematopoietic cells, little is known about the role of SHP1 in epithelial 
cells (55). In this study I explored the role of SHP1 in H. pylori CagA mediated 
carcinogenesis in gastric epithelial cells. The key findings in this study are the 
identification of SHP1 as a major and specific phosphatase that tyrosine- 
dephosphorylates Helicobacter pylori CagA oncoprotein and thereby attenuates CagA- 
mediated carcinogenesis in gastric epithelial cells. Here I found a novel interaction 
between SHP1 and H. pylori CagA, in gastric epithelial cells and B cells (Fig 1A, B). I 
also found that CagA acts as a binding partner and substrate for SHP1 in gastric 
epithelial cells. Unlike SHP2, the CagA-SHP1 interaction is independent of EPIYA-
tyrosine phosphorylation of CagA (Fig 2A, B, 3A). I also demonstrated that SHP1 
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directly binds to CagA and further established that, this interaction is mediated via N-
terminal region, which contains SH2 domains of SHP1 (Fig 3A, 4B). SH2 domains 
commonly recognize and bind phosphorylated-tyrosine, thereby trigger the formation of 
protein complexes in a ligand dependent manner (81). In the case of SHP1 SH2 
domains, a preference for phosphorylated-CagA in vitro was not observed. However, 
this is not unusual because the SH2 domains of SHP1 are known to often bind 
interacting partners/substrates in a phosphotyrosine-independent manner 
(9,30,32,46,47,82). My preliminary experiments indicated that the CagA-SHP1 
interaction, which is mediated by the N-terminal region of SHP1 does not seem to 
require functional-SH2 domains as the introduction of mutation into both of the SH2 
domains did not abolish SHP1 binding with CagA (data not shown). This indicates that 
CagA-SHP1 interaction is mediated by a novel mechanism that is totally different from 
the SH2 domains-phosphotyrosine interaction. 
The present study provided evidence that SHP1 efficiently dephosphorylates H. pylori 
oncoprotein CagA in gastric epithelial cells and in vitro. Expression of wild type SHP1 
but not the phosphatase-dead form of SHP1 resulted in the dephosphorylation of CagA 
(Fig 7B-C, 8A-B) consolidating that the dephosphorylation depends on the catalytic 
activity of SHP1. Furthermore, knockdown of SHP1 in AGS cells resulted in the up-
regulation of tyrosine phosphorylation of CagA (Fig 9). I also demonstrated that SHP1 
but not its structurally related family member SHP2 is the specific phosphatase for 
CagA (Fig 8C) further highlighting the specificity of SHP1 on CagA as a substrate. 
What are the biological significance for the functional interaction between SHP1 and H. 
pylori CagA oncoprotein? Expression of SHP1 resulted in the dephosphorylation and 
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down-regulation of tyrosine-phosphorylated CagA. Besides, ensuring a rapid down-
regulation of phosphotyrosine-dependent signaling by CagA, another possible 
consequence of the constitutive proximity of SHP1 to its substrates could be that such 
setup allows the substrate to feedback regulate SHP1 catalytic activity, as seen in other 
instances (32,30,82,37). For example, CagA interaction with the N-terminal region of 
SHP1, which contains SH2 domains, could release the conformation-dependent auto- 
inhibition of SHP1 (57). It was found that such CagA-SHP1 interaction resulted in the 
significant activation of SHP1 phosphatase activity (Fig 6). 
Inhibition of CagA tyrosine phosphorylation or disruption of the CagA-SHP2 complex 
formation might result in the attenuation of H. pylori CagA function. CagA-SHP2 
complex formation plays an important role in the progression of the multistep gastric 
carcinogenesis that is associated with cagA-positive H. pylori infection (24). Tyrosine 
phosphorylation of CagA is an essential prerequisite for CagA-SHP2 complex 
formation and subsequent induction of unique cell morphology termed hummingbird 
phenotype, which is associated with cell scattering and increased cell motility (5,24,63). 
I found that expression of SHP1 inhibited the ‘hummingbird phenotype’ caused by 
CagA-SHP2 interaction (Fig 10A, B), highlighting the role of SHP1 in counteracting 
the oncogenic potential of CagA.  
There are many reports with regard to expression level of SHP1 during cancer 
progression (10,14,15,36,38,68,77,85,86), in which expression of SHP1 is often 
suppressed and suggesting the important role played by SHP1 as a negative regulator of 
cell signaling. It was also reported recently that SHP1 expression is suppressed during 
the process of gastric carcinogenesis via promoter hyper-methylation, suggesting the 
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role of SHP1 as a tumor suppressor in the gastric epithelium (66). In this study, I found 
that SHP1 tyrosine phosphatase effectively tyrosine-dephosphorylates H. pylori 
oncoprotein CagA in gastric epithelial cells, thereby attenuating the pathophysiological 
action of CagA. Attenuation of H. pylori CagA activity by C-terminal Src kinase (CSK) 
has been reported previously (69). In that case CSK inhibits the kinase activity of Src, 
which tyrosine-phosphorylates CagA (69). The results of my study provides potentially 
important role of SHP1 in down-regulating the oncogenic activity of H. pylori CagA. In 
turn, the relatively low levels of SHP1 expression in gastric epithelial cells might 
contribute to the development of CagA-mediated carcinogenesis. At the same time, 
overexpression of SHP1 should almost completely abolish tyrosine phosphorylation of 
CagA and thus impairs the oncogenic potential of CagA, raising the idea that elevated 
levels of SHP1 in gastric epithelial cells could prevent gastric cancer development in 
patients infected by cagA-positive H. pylori. CagA-mediated cellular pathogenesis 
depends, at least partly, on relative levels of SHP2 expression in the host cells. In the 
present study, I found that high levels of SHP1 expression in gastric epithelial cells 
dampen the oncogenic potential of CagA. In normal gastric epithelial cells SHP2 
expression is relatively high compared to SHP1 
(http://157.82.78.238/refexa/main_search.jsp, Laboratory for Systems Biology and 
Medicine at RCAST, The University of Tokyo). Based on this, low expression of SHP1 
in gastric epithelial cells might contribute to the development of CagA-mediated 
pathogenesis where SHP2 is predominantly expressed. Development of a small 
compound that stimulates the phosphatase activity of SHP1 may be applicable to the 
prophylaxis of gastric cancer in individuals infected by H. pylori cagA-positive strains. 
Since SHP1 is abundantly expressed in hematopoietic cells including B-lymphocytes to 
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which CagA can also be delivered by H. pylori (44). And it is possible that high 
expression levels of SHP1 in lymphocytes might be one reason that explains the low 
incidence of MALT lymphoma compared to gastric cancer in patients infected with 
cagA-positive H. pylori. Given that SHP1 is occasionally hyper-methylated in gastric 
cancer cases (66), it should be important to elucidate the role for the relative levels of 
SHP1 and SHP2 expression in gastric epithelial cells in the development of stomach 
cancer by cagA-positive H. pylori. At present, there is no in vivo evidence to show how 
efficiently SHP1 can regulate H. pylori CagA-associated gastric carcinogenesis. 
However in my future work, I am interested to focus more on those aspects and other 
influences of SHP1 on the gastric oncogenic development by H. pylori CagA. 
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Figure 11 
    
Figure 11. A proposed model for the negative regulation of Helicobacter pylori 
CagA by SHP1 tyrosine phosphatase. Once translocated into the host cell via type IV 
secretion system H. pylori CagA undergoes tyrosine phosphorylation at the EPIYA-
motifs by Src family kinases and specifically forms complex with SHP2 tyrosine 
phosphatase in gastric epithelial cells and results in subsequent induction of unique cell-
morphology termed hummingbird phenotype. On the other hand in my studies it was 
found that CagA forms direct complex with SHP1 tyrosine phosphatase and activates its 
enzymatic activity. Furthermore, expression of SHP1 results in efficient 
dephosphorylation of CagA and thereby inhibits the hummingbird phenotype caused by 
CagA-SHP2 complex formation.   
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Conclusion 
In this study I demonstrated that the H. pylori oncoprotein CagA interacts directly with 
SHP1 tyrosine phosphatase. I also showed that expression of SHP1 in gastric epithelial 
cells results in the efficient tyrosine dephosphorylation of CagA and inhibits the unique 
cell morphology caused by tyrosine-phosphorylated CagA, thereby attenuates the 
pathogenic/oncogenic potential of H. pylori oncoprotein CagA in gastric epithelial cells. 
Given these it will be very helpful for our understanding of the mechanism of regulation 
of H. pylori-related gastric diseases, especially the gastric cancer, the second leading 
cause of cancer-related death worldwide and also MALT Lymphoma. 
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